



# THE ROLE OF SODIUM HYDROSULFIDE ON HYDROGEN SULFIDE GENERATING PATHWAY, NITRIC OXIDE PATHWAY, AND RENIN ANGIOTENSIN SYSTEM IN SPONTANEOUSLY HYPERTENSIVE RATS

You-Lin Tain<sup>1</sup> and Chien-Ning Hsu<sup>2</sup>

<sup>1</sup>Departments of Pediatrics and <sup>2</sup>Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

### 1. The gasotransmitters, hydrogen sulfide (H<sub>2</sub>S) and nitric oxide (NO), have been documented in hypertension.

- 2. Our previous reports showed that NO deficiency develops early in 4-week-old young spontaneously hypertensive rats (SHRs) and restoration of NO prevents the development of hypertension in young SHRs.
- 3. We examined whether sodium hydrosulfide, an exogenous H<sub>2</sub>S donor, can regulate endogenous H<sub>2</sub>S-generating pathway, mediate the balance between Larginine and N<sup>G</sup> monomethyl-L-arginine (L-NMMA, an inhibitor of NOS), and restore the RAS, to prevent the development of hypertension in SHR with a focus on the kidney.

Table 1. Weights and functional parameters

Groups	WKY	SHR	SHR+NaHS
Mortality	0%	0%	0%
Body weight (g)	283 ± 5	290 ± 5	254 ± 5 <sup>a,b</sup>
Left kidney weight (g)	1.16 ± 0.03	1.19 ± 0.02	0.98 ± 0.02 <sup>a,b</sup>
Left kidney weight/100 g BW	0.41 ± 0.004	0.411 ± 0.007	0.394 ± 0.008a
Heart weight (g)	0.99 ± 0.03	1.21 ± 0.02 <sup>a</sup>	1.05 ± 0.01 <sup>b</sup>
Heart weight/100 g BW	0.354 ± 0.005	0.424 ± 0.096a	0.413 ± 0.005 <sup>a</sup>
Systolic blood pressure (mm Hg)	153 ± 3	182 ± 3ª	167 ± 2 <sup>a,b</sup>
Diastolic blood pressure (mm Hg)	70 ± 3	96 ± 7ª	87 ± 3ª
Mean arterial pressure (mm Hg)	98 ± 3	125 ± 4ª	113 ± 2 <sup>a,b</sup>

 $N = 8/group; ^{a}P < 0.05 vs. WKY; ^{b}P < 0.05 vs. SHR$ 

Table 2. Plasma L-arginine, L-NMMA, homocysteine, Lcysteine, and glutathione levels

Groups	WKY	SHR	SHR+NaHS
L-arginine	252 ± 30	319 ± 10	211 ± 4 <sup>b</sup>
L-NMMA	511 ± 30	426 ± 52	260 ± 28 <sup>a,b</sup>
Homocysteine	3.77 ± 0.26	2.55 ± 0.15 <sup>a</sup>	2.33 ± 0.15 <sup>a</sup>
L-cysteine	173.5 ± 9.9	186.6 ± 4.8	184.5 ± 7.4
Glutathione	27 ± 0.8	32.5 ± 1.4 <sup>a</sup>	38.4 ± 3.4 <sup>a</sup>

 $N = 8/group; {}^{a}P < 0.05 \text{ vs. WKY}; {}^{b}P < 0.05 \text{ vs. SHR}$ 




Figure 1. Effect of NaHS on systolic blood pressure in 12-wk-old Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs), \*P<0.05 vs. WKY; #P<0.05 vs. SHR.




Figure 2. Effect of NaHS on (A) H<sub>2</sub>S production and (B) mRNA expression of H<sub>2</sub>S-generating enzymes in the kidney in 12-wk-old WKY rats and SHRs. \*P<0.05 vs. WKY; #p<0.05 vs. SHR.




Figure 3. Representative western blots (A) show CBS (~61kDa), CSE (~45kDa), and 3MST (~52kDa) in WKY rats and SHRs at 12 wk of age. Relative abundance of renal cortical (B) CBS, (C) CSE, and (D) 3MST. \*P<0.05 vs. WKY.




Figure 4. Simplified scheme of the interactions of H<sub>2</sub>S, NO, and RAS in the kidney by which NaHS therapy prevents the development of hypertension in SHRs.

- 1. Rats aged 4 weeks are randomly assigned into three groups (N = 8 for each group): Group1, WKY rats without treatment; Group 2, SHRs without treatment; and Group 3, SHR+NaHS, SHRs were injected intraperitoneally with NaHS (14 µmol/kg/day) for 4 weeks.
- 2. Plasma L-arginine, L-NMMA, homocysteine, L-cysteine, and glutathione levels were measured using HPLC (HP series 1100, Agilent Tec., Inc.)

- 1. NaHS blocks the development of hypertension in SHRs (Table 1; Figure 1).
- 2. NaHS increased renal H<sub>2</sub>S production in SHRs (Figure 2A).
- 3. NaHS reduces mRNA expression of 4 H2S-generating enzymes and decreased 3-mercaptopyruvate sulphurtransferase (3MST) protein level in SHR kidney. (Figure 2B; Figure 3D).
- 4. NaHS decreases plasma levels of Larginine and L-NMMA in SHR (Table 2).
- 5. Figure 4 is a simple schematic summarizing our results.

### CONCLUSIONS

- 1. We conclude that early exogenous H<sub>2</sub>S therapy by NaHS increased renal H<sub>2</sub>S production, restored the balance between L-arginine and L-NMMA, and inhibited the activation of RAS in the kidney, in favor of vasodilatation to prevent hypertension in SHRs.
- 2. The present study supports the assertion that early H<sub>2</sub>S treatment in childhood might prevent the transition from prehypertension to hypertension in adult life.

## ACKNOWLEDGMENTS

This work was supported by CMRPG8D0271 from Kaohsiung Chang Gung Memorial Hospital, Taiwan.







